92 related articles for article (PubMed ID: 23856460)
1. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
[TBL] [Abstract][Full Text] [Related]
2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
3. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.
Rampurwala M; Wisinski KB; Burkard ME; Ehsani S; O'Regan RM; Carmichael L; Kim K; Kolesar J; Tevaarwerk AJ
Invest New Drugs; 2017 Feb; 35(1):87-94. PubMed ID: 27826831
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
6. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M; Corn PG; Michaelson MD; Hammers HJ; Alumkal JJ; Ryan CJ; Bruce JY; Moran S; Lee SY; Lin HM; George DJ;
Clin Cancer Res; 2014 Aug; 20(16):4218-27. PubMed ID: 24965748
[TBL] [Abstract][Full Text] [Related]
8. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys.
Hara T; Araki H; Kusaka M; Harada M; Cho N; Suzuki N; Furuya S; Fujino M
J Clin Endocrinol Metab; 2003 Apr; 88(4):1697-704. PubMed ID: 12679460
[TBL] [Abstract][Full Text] [Related]
9. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
[TBL] [Abstract][Full Text] [Related]
10. Bioassay of circulating luteinizing hormone in the rhesus monkey: comparison with radioimmunoassay during physiological changes.
Dufau ML; Hodgen GD; Goodman AL; Catt KJ
Endocrinology; 1977 Jun; 100(6):1557-65. PubMed ID: 404130
[TBL] [Abstract][Full Text] [Related]
11. Orteronel for the treatment of prostate cancer.
Van Hook K; Huang T; Alumkal JJ
Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals.
Goto A; Moriya Y; Takeuchi T; Mandai T; Tagawa Y; Kondo T; Asahi S
Drug Res (Stuttg); 2016 Apr; 66(4):217-22. PubMed ID: 26418412
[TBL] [Abstract][Full Text] [Related]
13. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
Roviello G; Pacifico C; Chiriacò G; Generali D
Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
[TBL] [Abstract][Full Text] [Related]
14. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
Fraser HM; Nestor JJ; Vickery BH
Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer.
Suzuki K; Ozono S; Yamaguchi A; Koike H; Matsui H; Nagata M; Takubo T; Miyashita K; Matsushima T; Akaza H
Cancer Chemother Pharmacol; 2015 Feb; 75(2):373-80. PubMed ID: 25537627
[TBL] [Abstract][Full Text] [Related]
16. Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys.
Rotgeri A; Korolainen H; Sundholm O; Schmitz H; Fuhrmann U; Prelle K; Sacher F
Hum Reprod; 2015 Feb; 30(2):308-14. PubMed ID: 25432919
[TBL] [Abstract][Full Text] [Related]
17. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study.
Kumar A; S VK; Gurav S; Zainuddin M; Dewang P; Kethiri RR; Rajagopal S; Mullangi R
Biomed Chromatogr; 2013 Dec; 27(12):1590-4. PubMed ID: 23788266
[TBL] [Abstract][Full Text] [Related]
19. Levels of messenger ribonucleic acid for cytochrome P450 17 alpha-hydroxylase and P450 aromatase in preovulatory bovine follicles decrease after the luteinizing hormone surge.
Voss AK; Fortune JE
Endocrinology; 1993 May; 132(5):2239-45. PubMed ID: 8477668
[TBL] [Abstract][Full Text] [Related]
20. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
